KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Non Operating Income (2020 - 2026)

AbCellera Biologics filings provide 7 years of Non Operating Income readings, the most recent being $8.0 million for Q1 2026.

  • Quarterly Non Operating Income fell 17.51% to $8.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $19.1 million through Mar 2026, down 77.95% year-over-year, with the annual reading at -$2.7 million for FY2025, 104.35% down from the prior year.
  • Non Operating Income hit $8.0 million in Q1 2026 for AbCellera Biologics, up from -$153000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $32.2 million in Q2 2024 and bottomed at -$39.0 million in Q4 2023.
  • Average Non Operating Income over 5 years is $5.9 million, with a median of $3.6 million recorded in 2023.
  • The largest annual shift saw Non Operating Income crashed 270.43% in 2023 before it surged 1732.28% in 2024.
  • AbCellera Biologics' Non Operating Income stood at $22.9 million in 2022, then crashed by 270.43% to -$39.0 million in 2023, then soared by 135.21% to $13.7 million in 2024, then crashed by 101.12% to -$153000.0 in 2025, then skyrocketed by 5316.99% to $8.0 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Non Operating Income are $8.0 million (Q1 2026), -$153000.0 (Q4 2025), and -$2.0 million (Q3 2025).